Ceftobiprole: a new broad spectrum cephalosporin.

Abstract

Ceftobiprole, formerly designated BAL9141/Ro 63-9141, is a pyrrolidinone-3-ylidene-methyl cephalosporin with demonstrated in vitro activity against MRSA, Enterococcus faecalis, Enterobacteriaceae and Pseudomonas aeruginosa. Ceftobiprole has a low potential for inducing chromosomal AmpC beta-lactamases but it is hydrolyzed by most extended spectrum beta-lactamases and metallo-beta-lactamases. Glomerular filtration is predominantly responsible for removal of the free drug from the systemic circulation. The efficacy of ceftobiprole in the treatment of complicated skin and ski-structure infections has been recently demonstrated in two Phase III randomized clinical trials involving 1600 patients. Two other Phase III clinical trials to assess ceftobiprole's efficacy in community-acquired pneumonia and nosocomial pneumonia have also concluded. While the drug met the noninferiority criteria for community-acquired pneumonia and nosocomial pneumonia involving non-ventilator associated pneumonia, ceftobiprole was less effective than the comparator in ventilator associated pneumonia subjects. Ceftobiprole was well tolerated with a safety profile consistent with the cephalosporin class of antibiotic. The most frequent drug-related adverse event was dysgeusia. Ceftobiprole is intended for use in the hospital for the treatment of infections that frequently involve beta-lactam-resistant Gram-negative and Gram-positive organisms.

• Authors: Ali El Solh
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 10 Issue 10 Pg. 1675-86 (Jul 2009) ISSN: 1744-7666 [Electronic] England
• PMID: 19527192 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• Bacterial Proteins
• Cephalosporins
• Ro 63-9141
• ceftobiprole
• AmpC beta-lactamases
• beta-Lactamases

Topics

• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Bacterial Proteins (drug effects, metabolism)
• Cephalosporins (pharmacology, therapeutic use)
• Clinical Trials as Topic
• Clinical Trials, Phase III as Topic
• Cross Infection (drug therapy)
• Drug Interactions
• Enterococcus faecalis (drug effects)
• Gram-Positive Bacterial Infections (drug therapy)
• Humans
• Methicillin Resistance
• Methicillin-Resistant Staphylococcus aureus (drug effects, metabolism)
• Microbial Sensitivity Tests (statistics & numerical data)
• Treatment Outcome
• beta-Lactamases (drug effects, metabolism)